Pfizer, Inc. (PFE) Given Average Recommendation of “Hold” by Analysts

Pfizer, Inc. (NYSE:PFE) has received a consensus rating of “Hold” from the twenty-two analysts that are covering the company, MarketBeat reports. Two investment analysts have rated the stock with a sell recommendation, eight have given a hold recommendation and twelve have issued a buy recommendation on the company. The average 1 year price target among brokers that have covered the stock in the last year is $38.39.

PFE has been the subject of a number of research analyst reports. Jefferies Group LLC set a $39.00 price target on Pfizer and gave the stock a “neutral” rating in a report on Thursday, November 16th. Berenberg Bank reiterated a “hold” rating and set a $36.00 price target (down previously from $39.00) on shares of Pfizer in a report on Tuesday, August 15th. BidaskClub upgraded Pfizer from a “strong sell” rating to a “sell” rating in a report on Saturday, August 5th. Cowen and Company set a $43.00 price target on Pfizer and gave the stock a “buy” rating in a report on Monday, August 14th. Finally, UBS AG reiterated a “buy” rating and set a $38.00 price target on shares of Pfizer in a report on Monday, July 31st.

In related news, insider Alexander R. Mackenzie sold 7,350 shares of the business’s stock in a transaction on Thursday, August 31st. The shares were sold at an average price of $34.00, for a total value of $249,900.00. Following the sale, the insider now owns 132,124 shares of the company’s stock, valued at $4,492,216. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, insider Alexander R. Mackenzie sold 14,700 shares of the business’s stock in a transaction on Wednesday, November 1st. The stock was sold at an average price of $35.30, for a total transaction of $518,910.00. Following the completion of the sale, the insider now directly owns 117,432 shares in the company, valued at approximately $4,145,349.60. The disclosure for this sale can be found here. Insiders have sold 366,557 shares of company stock valued at $12,532,406 over the last quarter. Company insiders own 0.06% of the company’s stock.

A number of institutional investors and hedge funds have recently modified their holdings of the business. Northstar Group Inc. boosted its position in Pfizer by 0.4% during the second quarter. Northstar Group Inc. now owns 8,602 shares of the biopharmaceutical company’s stock valued at $289,000 after acquiring an additional 35 shares during the last quarter. Peregrine Asset Advisers Inc. boosted its position in Pfizer by 0.5% during the second quarter. Peregrine Asset Advisers Inc. now owns 7,354 shares of the biopharmaceutical company’s stock valued at $247,000 after acquiring an additional 35 shares during the last quarter. Northwest Quadrant Wealth Management LLC boosted its position in Pfizer by 0.8% during the second quarter. Northwest Quadrant Wealth Management LLC now owns 6,329 shares of the biopharmaceutical company’s stock valued at $211,000 after acquiring an additional 50 shares during the last quarter. River Wealth Advisors LLC boosted its position in Pfizer by 0.3% during the second quarter. River Wealth Advisors LLC now owns 15,818 shares of the biopharmaceutical company’s stock valued at $531,000 after acquiring an additional 55 shares during the last quarter. Finally, Meridian Wealth Management LLC boosted its position in Pfizer by 0.5% during the second quarter. Meridian Wealth Management LLC now owns 11,966 shares of the biopharmaceutical company’s stock valued at $402,000 after acquiring an additional 57 shares during the last quarter. 69.34% of the stock is currently owned by institutional investors and hedge funds.

WARNING: “Pfizer, Inc. (PFE) Given Average Recommendation of “Hold” by Analysts” was posted by TrueBlueTribune and is owned by of TrueBlueTribune. If you are reading this piece on another site, it was illegally stolen and republished in violation of international trademark & copyright legislation. The original version of this piece can be viewed at https://www.truebluetribune.com/2017/11/21/pfizer-inc-pfe-given-average-recommendation-of-hold-by-analysts.html.

Shares of Pfizer (NYSE PFE) opened at $35.35 on Tuesday. The company has a quick ratio of 1.15, a current ratio of 1.43 and a debt-to-equity ratio of 0.56. The stock has a market capitalization of $211,040.00, a PE ratio of 14.15, a P/E/G ratio of 2.50 and a beta of 1.01. Pfizer has a 12-month low of $30.51 and a 12-month high of $36.78.

Pfizer (NYSE:PFE) last released its earnings results on Tuesday, October 31st. The biopharmaceutical company reported $0.67 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.65 by $0.02. The business had revenue of $13.17 billion for the quarter, compared to the consensus estimate of $13.17 billion. Pfizer had a return on equity of 25.41% and a net margin of 18.69%. Pfizer’s quarterly revenue was up .9% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.61 earnings per share. research analysts expect that Pfizer will post 2.6 EPS for the current year.

The business also recently declared a quarterly dividend, which will be paid on Friday, December 1st. Stockholders of record on Friday, November 10th will be issued a dividend of $0.32 per share. The ex-dividend date of this dividend is Thursday, November 9th. This represents a $1.28 annualized dividend and a dividend yield of 3.62%. Pfizer’s dividend payout ratio (DPR) is presently 78.53%.

About Pfizer

Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).

Analyst Recommendations for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply